Q4 2023 · 13F-HR/A
Commodore Capital LPholdings as filed
Filed 2024-02-14 · accession 0001831942-24-000003
$1.14B
Reported value
32
Positions
2023-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| N5749R100 | 2GH | MERUS N V | $130.6M | 11.4% | 4,747,373 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $99.8M | 8.72% | 2,167,793 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $98.0M | 8.56% | 1,331,037 | Common | SOLE |
| 92337R101 | VERA | VERA THERAPEUTICS INC | $83.8M | 7.32% | 5,450,000 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $71.3M | 6.23% | 1,550,000 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $69.1M | 6.04% | 1,100,000 | Common | SOLE |
| 12674W109 | CABA | CABALETTA BIO INC | $43.1M | 3.77% | 1,900,000 | Common | SOLE |
| 45258J102 | IMVT | IMMUNOVANT INC | $42.1M | 3.68% | 1,000,000 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $41.9M | 3.66% | 1,924,074 | Common | SOLE |
| 04335A105 | ARVN | ARVINAS INC | $41.2M | 3.60% | 1,000,000 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $40.5M | 3.54% | 1,884,084 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $40.2M | 3.51% | 2,901,816 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $32.7M | 2.86% | 5,566,026 | Common | SOLE |
| 02083G100 | NVLSEUR | ALPINE IMMUNE SCIENCES INC | $30.7M | 2.68% | 1,610,000 | Common | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $28.2M | 2.46% | 700,000 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $27.8M | 2.43% | 701,967 | Common | SOLE |
| 15102K100 | CELC | CELCUITY INC | $25.6M | 2.23% | 1,754,704 | Common | SOLE |
| 75525N107 | — | RAYZEBIO INC | $23.9M | 2.08% | 383,638 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $22.4M | 1.96% | 800,000 | Common | SOLE |
| 12529R107 | CCCC | C4 THERAPEUTICS INC | $21.5M | 1.88% | 3,800,000 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $20.3M | 1.77% | 1,895,003 | Common | SOLE |
| 65487U108 | NKTX | NKARTA INC | $18.0M | 1.57% | 2,730,000 | Common | SOLE |
| 50127T109 | KURA | KURA ONCOLOGY INC | $17.9M | 1.57% | 1,248,062 | Common | SOLE |
| 41358P205 | HARPUSD | HARPOON THERAPEUTICS INC | $17.1M | 1.49% | 1,500,000 | Common | SOLE |
| 00973Y108 | AKRO | AKERO THERAPEUTICS INC | $13.2M | 1.15% | 565,000 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $12.0M | 1.05% | 900,000 | Common | SOLE |
| 92840H400 | VTGN | VISTAGEN THERAPEUTICS INC | $8.1M | 0.71% | 1,575,000 | Common | SOLE |
| 88427A107 | — | THIRD HARMONIC BIO INC | $7.8M | 0.68% | 706,706 | Common | SOLE |
| 00773U108 | ADVMCHF | ADVERUM BIOTECHNOLOGIES INC | $7.5M | 0.66% | 10,000,000 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $7.0M | 0.61% | 250,000 | Common | SOLE |
| 78397T202 | SABS | SAB BIOTHERAPEUTICS INC | $1.3M | 0.11% | 1,831,746 | Common | SOLE |
| 23306J101 | — | DBV TECHNOLOGIES S A | $88,312 | 0.01% | 92,687 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.